Questioning Mylan on the Rising Price of EpiPens

Last week, the House Oversight Committee held a hearing to investigate the massive increase in the price of EpiPens. Drug pricing is overly complex and in the last few years we have seen several examples of companies purchasing drugs and driving the prices up dramatically to increase profits. When Mylan aquired the EpiPen several years ago it cost around $100 for a pair of EpiPens (one dose). However, recently the company raised the price of the drug to more than $600 a pack- more expensive than most families can afford.

While I believe in free markets, raising the price of a life-saving drug more than 600% does not pass the smell test. During the hearing, Mylan CEO Heather Bresch faced strong backlash from legislators on both sides of the aisle for the company's behavior. Millions of Americans rely on an EpiPen when seconds count to stop an allergic reaction, and they should be affordable.